Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.
Zhao R
,
Qiu A
,
Tsai E
,
Jansen M
,
Akabas MH
,
Goldman ID
.
???displayArticle.abstract???
The reduced folate carrier (RFC) and the proton-coupled folate transporter (PCFT) are ubiquitously expressed in normal and malignant mammalian tissues and in human solid tumor cell lines. This article addresses the extent to which PCFT contributes to transport of pemetrexed and to the activities of this and other antifolates relative to RFC at physiological pH. Either RFC or PCFT cDNA was stably transfected into a transporter-null HeLa cell variant to achieve activities similar to their endogenous function in wild-type HeLa cells. PCFT and RFC produced comparable increases in pemetrexed activity in growth medium with 5-formyltetrahydrofolate. However, PCFT had little or no effect on the activities of methotrexate, N-(5-[N-(3,4-dihydro-2-methyl-4-oxyquinazolin-6-ylmethyl)-N-methyl-amino]-2-thenoyl)-l-glutamic acid (raltitrexed, Tomudex; ZD1694), or N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-l-ornithine (PT523) in comparison with RFC irrespective of the folate growth source. PCFT, expressed at high levels in Xenopus laevis oocytes and in transporter-competent HepG2 cells, exhibited a high affinity for pemetrexed, with an influx K(m) value of 0.2 to 0.8 muM at pH 5.5. PCFT increased the growth inhibitory activity of pemetrexed, but not that of the other antifolates in HepG2 cells grown with 5-formyltetrahydrofolate at physiological pH. These findings illustrate the unique role that PCFT plays in the transport and pharmacological activity of pemetrexed. Because of the ubiquitous expression of PCFT in human tumors, and the ability of PCFT to sustain pemetrexed activity even in the absence of RFC, tumor cells are unlikely to become resistant to pemetrexed as a result of impaired transport because of the redundancy of these genetically distinct routes.
Andreassi,
Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors.
2002, Pubmed
Andreassi,
Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors.
2002,
Pubmed
Chattopadhyay,
Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
2007,
Pubmed
Chattopadhyay,
The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
2006,
Pubmed
Gorlick,
Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.
1997,
Pubmed
Guo,
Mechanisms of methotrexate resistance in osteosarcoma.
1999,
Pubmed
Helmlinger,
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation.
1997,
Pubmed
Henderson,
Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells.
1983,
Pubmed
Henderson,
Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells.
1990,
Pubmed
Kamen,
The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro.
1991,
Pubmed
Kamen,
A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro.
2004,
Pubmed
Matherly,
Membrane transport of folates.
2003,
Pubmed
Matherly,
Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.
1995,
Pubmed
Piedrahita,
Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development.
1999,
Pubmed
Prasad,
Functional coupling between a bafilomycin A1-sensitive proton pump and a probenecid-sensitive folate transporter in human placental choriocarcinoma cells.
1994,
Pubmed
Qiu,
Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction.
2007,
Pubmed
,
Xenbase
Qiu,
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
2006,
Pubmed
,
Xenbase
Salazar,
The folate receptor: what does it promise in tissue-targeted therapeutics?
2007,
Pubmed
Sharif,
Rapid determination of membrane transport parameters in adherent cells.
2000,
Pubmed
Skehan,
New colorimetric cytotoxicity assay for anticancer-drug screening.
1990,
Pubmed
Westerhof,
Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
1995,
Pubmed
Wike-Hooley,
The relevance of tumour pH to the treatment of malignant disease.
1984,
Pubmed
Wollack,
Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model.
2008,
Pubmed
Wong,
Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier.
1998,
Pubmed
Yang,
Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles.
1983,
Pubmed
Zhao,
The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed.
2007,
Pubmed
Zhao,
The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption.
2007,
Pubmed
Zhao,
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
2000,
Pubmed
Zhao,
Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
2004,
Pubmed
Zhao,
Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
2004,
Pubmed
Zhao,
A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
2004,
Pubmed
Zhao,
Resistance to antifolates.
2003,
Pubmed
Zhao,
Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs.
2001,
Pubmed
